Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of two drug combinations Cabotegravir Ultra Long-Acting CAB ULA plus Rilpivirine Ultra Long-Acting RPV ULA, and Cabotegravir Long-Acting CAB LA plus Rilpivirine Long-Acting RPV LA in adults and adolescents living with HIV who have their virus suppressed through antiretroviral therapy ART. This phase III trial aims to compare these treatments to understand their impact on maintaining viral suppression. Participants receive either the CAB ULA plus RPV ULA combination or the CAB LA plus RPV LA combination. These medications are administered as long-acting injectable drugs. The study uses a randomized, parallel-group design where participants are assigned to one of these two treatment groups to compare outcomes over time. During the trial, participants will be monitored closely with regular assessments including measuring plasma HIV-RNA levels, tracking any virologic failure, and evaluating drug-related adverse events. Laboratory tests will monitor drug concentrations and immune cell counts CD4 cells. The main outcome is the percentage of participants with HIV-RNA levels above 50 copiesmL at month 11. The study follows participants for up to 23 months to assess longer-term effects and safety.
Actively Recruiting
Researchers are studying the effectiveness and safety of Dolutegravir combined with Lamivudine compared to other antiretroviral regimens in pregnant women who have HIV-1 and have not received prior treatment. The study focuses on how well these treatments reduce the viral load in mothers and prevent HIV transmission to their newborns. It also looks at maternal side effects, birth outcomes, immune system changes, and resistance to treatment during pregnancy. Participants receive one of two drug regimens Dolutegravir plus Lamivudine taken once daily as a single tablet, or Dolutegravir combined with either TenofovirEmtricitabine or TenofovirLamivudine daily tablets. The study is randomized and open-label, meaning participants are assigned to groups by chance without placebo, and treatment is observed openly. Treatment continues through pregnancy until six months after delivery, with monitoring of viral load and other health indicators. During the study, participants will have regular visits for blood tests measuring viral load, immune cell counts, drug resistance, and safety labs. The babies will be tested at birth, six weeks, and six months to check for HIV infection. Researchers will track maternal weight gain, pregnancy outcomes, side effects, and whether the women need to change their treatment before delivery. The total involvement lasts about 14 months, depending on when participants join during pregnancy.
Actively Recruiting
Researchers are evaluating doravirine as an alternative to dolutegravir in people newly diagnosed with HIV-1 infection who have not yet received treatment. This Phase III, open-label, randomized clinical trial aims to determine if doravirine combined with tenofovir and lamivudine is not less effective than dolutegravir combined with tenofovir and lamivudine or emtricitabine. The study will be conducted across multiple countries including Brazil, Cameroon, Cte dIvoire, France, Mozambique, and Thailand, enrolling 610 participants. Participants will be randomly assigned to one of two groups one receiving doravirine 100 mg plus tenofovir DF 300 mg and lamivudine 300 mg daily, and the other receiving dolutegravir 50 mg plus tenofovir DF 300 mg and either lamivudine or emtricitabine daily. The treatment period will last for 96 weeks after starting antiretroviral therapy ART, with primary assessment at week 48 to measure viral suppression. During the study, participants will undergo evaluations to monitor viral load, drug resistance, metabolic health, body weight changes, liver and kidney function, cardiovascular status, and mental health. Adherence to ART will be tracked, and blood samples will be taken to measure drug levels and immune cell counts. The research team will review virological efficacy and safety outcomes at weeks 48 and 96, supporting a comprehensive understanding of the treatments effects over nearly two years of participation.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how well long-acting lenacapavir works to prevent HIV infection in people at higher risk in Brazil. The study aims to assess safety, continued use over time, and participant preference compared to daily oral pre-exposure prophylaxis PrEP. It focuses on how many participants get HIV while using lenacapavir, its safety in real-world health settings, and factors affecting ongoing prevention use. Participants can choose between two prevention options injections of long-acting lenacapavir under the skin every six months or daily oral PrEP pills containing tenofovir disoproxil fumarate and emtricitabine. Those choosing lenacapavir receive an oral loading dose followed by subcutaneous injections at enrollment and every six months, up to four injections during follow-up. Those choosing oral PrEP take daily pills with regular medication dispensing and follow-up visits. Both groups receive prevention counseling, regular HIV testing, and screening for sexually transmitted infections and viral hepatitis. Participants will visit clinics regularly for HIV testing, health checkups, and safety monitoring. They will answer questions about their health, medication use, and experiences, while researchers evaluate adherence, injection site reactions, and adverse events. The study will track persistence on lenacapavir over 24 months and time to discontinuation. This research will help health services understand how to offer and support long-acting HIV prevention in Brazil, with follow-up lasting up to two years.
Actively Recruiting
Healthy Volunteer
This research aims to improve access to HIV prevention by increasing the use of pre-exposure prophylaxis PrEP among underserved groups in Rio de Janeiro, including gay and bisexual men, transgender women, and sex workers. It focuses on populations at higher risk who face obstacles to accessing and continuing PrEP, especially those living in socially and economically vulnerable communities. The study evaluates whether delivering PrEP through community-based settings can enhance uptake and continued use. Participants will receive HIV prevention services in non-traditional community settings such as non-governmental organizations and mobile health units. Daily oral PrEP with tenofovir disoproxil fumarateemtricitabine will be offered to those who test HIV-negative, alongside counseling and follow-up support. Telehealth consultations and mobile health mHealth tools will also be used to support adherence and retention. Those who test positive for HIV will be referred to appropriate treatment within the public health system. During the study, participants will undergo HIV testing, counseling, and clinical monitoring. Data will be collected through questionnaires and clinical assessments to evaluate PrEP uptake, adherence, retention, and HIV incidence over up to 12 months. Follow-up focus groups will provide insights into participants experiences with community-based PrEP delivery. The study will monitor the feasibility and acceptability of this approach and assess engagement with digital support tools.